Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mayne Pharma Group Limited
  6. News
  7. Summary
    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mayne Pharma : Change of Director's Interest Notice

09/02/2021 | 03:32am EDT

Appendix 3Y

Change of Director's Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity

Mayne Pharma Group Limited

ABN

76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director

Frank Charles Condella Jr

Date of last notice

2 Sep 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest

Direct

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances

giving rise to the relevant interest.

Date of change

1 Sep 2021

No. of securities held prior to

343,428 Ordinary Full Paid Shares

change

Class

Ordinary shares

Number acquired

412,121

Number disposed

Nil

Value/Consideration

$136,679.93

Note: If consideration is non-cash, provide

details and estimated valuation

No. of securities held after

755,549 Ordinary Full Paid Shares

change

+ See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

ME_131678062_1 (W2003)

Appendix 3Y

Change of Director's Interest Notice

Nature of change

On-market trade

Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract

Nature of interest

Name of registered holder

(if issued securities)

Date of change

No. and class of securities to

which interest related prior to

change

Note: Details are only required for a contract in

relation to which the interest has changed

Interest acquired

Interest disposed

Value/Consideration

Note: If consideration is non-cash, provide details

and an estimated valuation

Interest after change

Part 3 - +Closed period

Were the interests in the securities or contracts

No

detailed above traded during a +closed period where

prior written clearance was required?

If so, was prior written clearance provided to allow

N/a

the trade to proceed during this period?

If prior written clearance was provided, on what

N/a

date was this provided?

+ See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

ME_131678062_1 (W2003)

Disclaimer

Mayne Pharma Group Limited published this content on 02 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 September 2021 07:31:05 UTC.


ę Publicnow 2021
All news about MAYNE PHARMA GROUP LIMITED
10/07MITHRA PHARMACEUTICALS S A : Provides FDA Update on Myring
AQ
10/07MAYNE PHARMA : Provides fda update on generic nuvaringo
AQ
10/06MAYNE PHARMA : to Address US FDA Feedback on Generic Version of Birth Control Product
MT
10/06MAYNE PHARMA : 07/10/2021áMayne Pharma provides FDA update on generic NUVARING
PU
10/06Mayne Pharma Provides US Food and Drug Administration Update on Generic NUVARING
CI
10/05MITHRA PHARMACEUTICALS S A : Announces the Appointment of its Representative to Mayne Phar..
AQ
10/04MAYNE PHARMA : appoints new Director
PU
10/03Mayne Pharma Group Limited Appoints Carolyn Myers to the Board
CI
09/30MAYNE PHARMA : Upsher-Smith Launches Three Additional Strengths of Isotretinoin Capsules
AQ
09/29MAYNE PHARMA : Adds generic absorica to us dermatology portfolio
AQ
More news
Financials
Sales 2022 461 M 342 M 342 M
Net income 2022 -26,7 M -19,8 M -19,8 M
Net Debt 2022 257 M 191 M 191 M
P/E ratio 2022 -16,0x
Yield 2022 -
Capitalization 547 M 406 M 406 M
EV / Sales 2022 1,74x
EV / Sales 2023 1,42x
Nbr of Employees 967
Free-Float 77,2%
Chart MAYNE PHARMA GROUP LIMITED
Duration : Period :
Mayne Pharma Group Limited Technical Analysis Chart | MYX | AU000000MYX0 | MarketScreener
Technical analysis trends MAYNE PHARMA GROUP LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,31 AUD
Average target price 0,45 AUD
Spread / Average Target 44,2%
EPS Revisions
Managers and Directors
Scott Richards Chief Executive Officer, MD & Executive Director
Peter Paltoglou Chief Financial Officer
Frank C. Condella Chairman
Gerard G. Nahum Chief Medical Officer
Keith Moore Vice President-Research & Development